A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
Status:
Not yet recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
The goal of this type of clinical trial is t to answer the following question: Can the chance
of colorectal cancer progressing be lowered by taking a medication, QBECO, before and after
surgery? The goal of this study is to find out if this approach is better or worse than the
standard of care for your type of cancer. The standard of care is defined as care most people
get for metastatic colorectal cancer. There is currently no standard of care drug being given
before or after surgery to prevent further spread of your cancer. Participants will be asked
to self-inject the study medication before surgery for minimum of 11 days and after surgery
for minimum of 41 days. Participants will be followed up every 3 months for 2 years, with a
final visit at year 5.